<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03228017</url>
  </required_header>
  <id_info>
    <org_study_id>17-00692</org_study_id>
    <nct_id>NCT03228017</nct_id>
  </id_info>
  <brief_title>Subclinical Cardiovascular Disease in Psoriatic Disease</brief_title>
  <official_title>Subclinical Cardiovascular Disease in Psoriatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at how chronic inflammation seen in psoriatic disease translates into&#xD;
      the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk.&#xD;
      The Aim of this study is to 1) Evaluate the association between moderate to severe psoriatic&#xD;
      disease and measures of vascular function. 2) Evaluate the association between moderate to&#xD;
      severe psoriatic disease and measures of thrombotic risk. 3) Understand how traditional&#xD;
      medications used in cardiovascular disease (CVD) prevention such as aspirin and statins&#xD;
      affect vascular function and thrombotic risk in those with moderate to severe psoriatic&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease (CVD) remains the leading cause of death in the US. Five modifiable&#xD;
      risk factors: smoking, hyperlipidemia, diabetes, hypertension and obesity, account for 50% of&#xD;
      CVD mortality between the ages of 45 - 79.1 These traditional cardiac risk factors dictate&#xD;
      who to treat with primary prevention measures but do not take into account patient-specific&#xD;
      disease states such as psoriatic disease including psoriasis and psoriatic arthritis, which&#xD;
      predispose to chronic inflammation. Patients with psoriatic disease have an increased risk of&#xD;
      atherosclerotic heart disease and myocardial infarctions compared to matched controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">April 1, 2019</completion_date>
  <primary_completion_date type="Actual">April 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Fold Change in Brachial Vein Endothelial Inflammatory Transcript</measure>
    <time_frame>Baseline, 5 Months</time_frame>
    <description>Endothelial sampling coupled to real-time PCR analysis will be used to monitor brachial vein endothelial inflammation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fold Change Change in Composite Endothelial Inflammation</measure>
    <time_frame>Baseline (pre-Aspirin), 2 weeks (post-Aspirin)</time_frame>
    <description>Endothelial inflammation will be monitored after 2 weeks of aspirin 81mg therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold Change in Composite Endothelial Inflammation</measure>
    <time_frame>Baseline (pre-Atorvastatin), 2 weeks (post-Atorvastatin)</time_frame>
    <description>Endothelial inflammation will be monitored after 2- weeks of 40mg of atorvastatin therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Levels of Circulating Thromboxane B2</measure>
    <time_frame>Baseline (pre-Aspirin), 2 weeks (post-Aspirin)</time_frame>
    <description>Platelet activation is measured by levels of circulating thromboxane b2, which will be measured after 2- weeks of aspirin 81mg therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <condition>Thrombotic Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Psoriatic Disease Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Moderate to severe psoriatic disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin and/or Atorvastatin</intervention_name>
    <description>This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.</description>
    <arm_group_label>Psoriatic Disease Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with a history of moderate to severe psoriatic disease&#xD;
&#xD;
          -  Group 2: Healthy subjects without known psoriatic disease or cardiovascular disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to speak Spanish or English&#xD;
&#xD;
          -  Active smoking (within the past year)&#xD;
&#xD;
          -  Autoimmune, rheumatologic or inflammatory disease which are not psoriasis or psoriatic&#xD;
             arthritis&#xD;
&#xD;
          -  Known active cancer receiving treatment&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Anemia (hemoglobin &lt; 9 mg/dl) or thrombocytopenia (Platelet count &lt;75), or&#xD;
             thrombocytosis (Platelet count &gt;600)&#xD;
&#xD;
          -  A history of severe bleeding or bleeding disorders&#xD;
&#xD;
          -  Current medication use which interact with either aspirin or atorvastatin&#xD;
&#xD;
          -  Chronic kidney disease (CrCl &lt; 30ml/min)&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Currently taking aspirin or a statin.&#xD;
&#xD;
          -  NSAID use within the past 48 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Berger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <results_first_submitted>March 5, 2021</results_first_submitted>
  <results_first_submitted_qc>August 31, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 28, 2021</results_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular disease</keyword>
  <keyword>CVD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03228017/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Psoriatic Disease Patients</title>
          <description>Moderate to severe psoriatic disease&#xD;
Aspirin and/or Atorvastatin: This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.</description>
        </group>
        <group group_id="P2">
          <title>Healthy Control</title>
          <description>Healthy Control</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Psoriatic Disease Patients</title>
          <description>Moderate to severe psoriatic disease&#xD;
Aspirin and/or Atorvastatin: This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.</description>
        </group>
        <group group_id="B2">
          <title>Healthy Control</title>
          <description>Healthy Control</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="14.2"/>
                    <measurement group_id="B2" value="40.5" spread="12.7"/>
                    <measurement group_id="B3" value="42.75" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Fold Change in Brachial Vein Endothelial Inflammatory Transcript</title>
        <description>Endothelial sampling coupled to real-time PCR analysis will be used to monitor brachial vein endothelial inflammation</description>
        <time_frame>Baseline, 5 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psoriatic Disease Patients</title>
            <description>Moderate to severe psoriatic disease&#xD;
Aspirin and/or Atorvastatin: This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>Healthy Control</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Fold Change in Brachial Vein Endothelial Inflammatory Transcript</title>
          <description>Endothelial sampling coupled to real-time PCR analysis will be used to monitor brachial vein endothelial inflammation</description>
          <units>Fold Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="8.6"/>
                    <measurement group_id="O2" value="2.8" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change Change in Composite Endothelial Inflammation</title>
        <description>Endothelial inflammation will be monitored after 2 weeks of aspirin 81mg therapy</description>
        <time_frame>Baseline (pre-Aspirin), 2 weeks (post-Aspirin)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psoriatic Disease Patients</title>
            <description>Moderate to severe psoriatic disease&#xD;
Aspirin and/or Atorvastatin: This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>Healthy Control</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change Change in Composite Endothelial Inflammation</title>
          <description>Endothelial inflammation will be monitored after 2 weeks of aspirin 81mg therapy</description>
          <units>Fold Change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" lower_limit="-0.4" upper_limit="-.15"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-0.17" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change in Composite Endothelial Inflammation</title>
        <description>Endothelial inflammation will be monitored after 2- weeks of 40mg of atorvastatin therapy.</description>
        <time_frame>Baseline (pre-Atorvastatin), 2 weeks (post-Atorvastatin)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psoriatic Disease Patients</title>
            <description>Moderate to severe psoriatic disease&#xD;
Aspirin and/or Atorvastatin: This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>Healthy Control</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change in Composite Endothelial Inflammation</title>
          <description>Endothelial inflammation will be monitored after 2- weeks of 40mg of atorvastatin therapy.</description>
          <units>Fold Change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-.21" upper_limit="-0.003"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-.04" upper_limit="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Levels of Circulating Thromboxane B2</title>
        <description>Platelet activation is measured by levels of circulating thromboxane b2, which will be measured after 2- weeks of aspirin 81mg therapy</description>
        <time_frame>Baseline (pre-Aspirin), 2 weeks (post-Aspirin)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psoriatic Disease Patients</title>
            <description>Moderate to severe psoriatic disease&#xD;
Aspirin and/or Atorvastatin: This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>Healthy Control</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Levels of Circulating Thromboxane B2</title>
          <description>Platelet activation is measured by levels of circulating thromboxane b2, which will be measured after 2- weeks of aspirin 81mg therapy</description>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.8"/>
                    <measurement group_id="O2" value="4.05" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Psoriatic Disease Patients</title>
          <description>Moderate to severe psoriatic disease&#xD;
Aspirin and/or Atorvastatin: This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.</description>
        </group>
        <group group_id="E2">
          <title>Healthy Control</title>
          <description>Healthy Control</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael Garshick</name_or_title>
      <organization>NYU Langone</organization>
      <phone>212-263-0855</phone>
      <email>michael.garshick@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

